These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18047776)

  • 21. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.
    Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):107-19. PubMed ID: 18031594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
    Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F
    Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.
    Ellis AG; Reginster JY; Luo X; Cappelleri JC; Chines A; Sutradhar S; Jansen JP
    Value Health; 2014 Jun; 17(4):424-32. PubMed ID: 24969003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
    Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
    Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
    Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
    Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
    Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.
    Miller PD; Delmas PD; Huss H; Patel KM; Schimmer RC; Adami S; Recker RR
    Calcif Tissue Int; 2010 Oct; 87(4):305-13. PubMed ID: 20737140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
    Harris ST; Reginster JY; Harley C; Blumentals WA; Poston SA; Barr CE; Silverman SL
    Bone; 2009 May; 44(5):758-65. PubMed ID: 19168160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
    Miller PD; Epstein S; Sedarati F; Reginster JY
    Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
    Miller PD; Recker RR; Reginster JY; Riis BJ; Czerwinski E; Masanauskaite D; Kenwright A; Lorenc R; Stakkestad JA; Lakatos P
    Osteoporos Int; 2012 Jun; 23(6):1747-56. PubMed ID: 21953471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
    Krege JH; Wan X
    Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
    Mendes D; Penedones A; Alves C; Oliveira T; Donato A; Batel-Marques F
    J Clin Rheumatol; 2023 Mar; 29(2):78-83. PubMed ID: 36731043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.